Esmolol Effects on Heart and Inflammation in Septic Shock (ESMOSEPSIS)
Anti-inflammatory and Cardiac Effects of Esmolol in Septic Shock. ESMOSEPSIS Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Nancy, France, 54511
- Recruiting
- CHU de Nancy
-
Contact:
- Bruno Levy, MD PhD
- Phone Number: 0033383154469
- Email: b.levy@chu-nancy.fr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- septic shock patients following the definition of the Surviving Sepsis Campaign
- femoral and central venous catheters for thermodilution monitoring
- fluid optimization
- with a cardiac index > 3 l/min/m2
- Heart Rate >100 /min
Exclusion Criteria:
- Cardiogenic shock
- Bradycardia
- History of Severe Asthma
- Indications against esmolol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: ESMOLOL
Resuscitated, hyperkinetic septic shock patients are treated with esmolol in order to reduce heart rate of 20% during 6 hours.
During the intervention period, multimodal macro and micro hemodynamic data are recorded.
|
After, at least six hours of hemodynamic optimization, patients with an hyper dynamic shock received a conventional management with a continuous infusion of Esmolol titrated to gain a 20% reduction in heart rate.
This infusion is maintained for six hours.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hemodynamic effects of Esmolol in septic shock patients (Value of cardiac index l/min/m2)
Time Frame: Before administration (H0) and each hour (H1-H2-H3-H4-H5-H6) during the whole administration period and one hour after Esmolol cessation (H7)
|
Compare, in septic shock patients, the mean cardiac index before and after administration of Esmolol.
|
Before administration (H0) and each hour (H1-H2-H3-H4-H5-H6) during the whole administration period and one hour after Esmolol cessation (H7)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Effects on vasopressor requirement (amount of norepinephrine infused in microgram/kg) during Esmolol administration
Time Frame: Record of each change in vasopressor dosage to maintain a mean arterial pressure at 70 mmHg during the whole Esmolol administration period (H0 to H6) and one hour after esmolol cessation (H7)
|
Record of each change in vasopressor dosage to maintain a mean arterial pressure at 70 mmHg during the whole Esmolol administration period (H0 to H6) and one hour after esmolol cessation (H7)
|
|
|
Microcirculatory and regional circulation effects of Esmolol in septic shock patient
Time Frame: Before (H0), 6 hours after Esmolol introduction (H6) and 1 hour after esmolol cessation (H7)
|
NIRS (near-infrared spectroscopy) SDF (Sidestream Dark Field imaging) / Limon (non-invasive measurement of liver function and splanchnic perfusion monitoring) are used to asses microcirculatory and regional circulation effects
|
Before (H0), 6 hours after Esmolol introduction (H6) and 1 hour after esmolol cessation (H7)
|
|
Changes in the Cytokine pattern(pro and anti inflammatory cytokines assay) induced by Esmolol administration in septic shock patients
Time Frame: Before administration of Esmolol (H0) and 6 hours after introduction of Esmolol (H6)
|
Before administration of Esmolol (H0) and 6 hours after introduction of Esmolol (H6)
|
|
|
Description of the cardiac function during Esmolol Administration in septic shock patients
Time Frame: Before administration (H0), at 4 hours, 6 hours after introduction and 1 hours after esmolol cessation
|
Use of Echocardiography to assess ventricular function
|
Before administration (H0), at 4 hours, 6 hours after introduction and 1 hours after esmolol cessation
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Bruno Levy, MD PhD, CHU de Nancy
- Principal Investigator: Antoine Kimmoun, MD, CHU de Nancy
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Infections
- Systemic Inflammatory Response Syndrome
- Inflammation
- Sepsis
- Shock, Septic
- Shock
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Adrenergic beta-1 Receptor Antagonists
- Esmolol
Other Study ID Numbers
Other Study ID Numbers
- 2012-004532-32
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.